The impact of structural biology in medicine illustrated with four case studies

Journal of Molecular Medicine

Volumn 96, Issue 1, 2018, Pages 9-19

  Hu, Tiancen ^a   Sprague, Elizabeth R ^a   Fodor, Michelle ^a   Stams, Travis ^a   Clark, Kirk L ^a   Cowan Jacob, Sandra W ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allosteric; Conformation; Drug discovery; Inhibitors; Structural biology

Indexed keywords

BIOLOGICAL PRODUCT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN TYROSINE KINASE;

CANCER IMMUNOTHERAPY; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; HUMAN; MALIGNANT NEOPLASM; MOLECULAR MEDICINE; MOLECULAR WEIGHT; NONHUMAN; REVIEW; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROTEIN CONFORMATION;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS; IMMUNOTHERAPY; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN CONFORMATION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 85021704747     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-017-1565-x     Document Type: Review

References (86)

1. Berman HM, Bhat TN, Bourne PE, Feng Z, Gilliland G, Weissig H, Westbrook J (2000) The protein data Bank and the challenge of structural genomics. Nat Struct Biol 7(Suppl):957–959
2. Ostrem JM, Shokat KM (2016) Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov 15:771–785
3. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744
4. Donegan RK, Hill SE, Freeman DM, Nguyen E, Orwig SD, Turnage KC, Lieberman RL (2015) Structural basis for misfolding in myocilin-associated glaucoma. Hum Mol Genet 24:2111–2124
5. Scott DE, Bayly AR, Abell C, Skidmore J (2016) Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov 15:533–550
6. Petzold G, Fischer ES, Thoma NH (2016) Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4 (CRBN) ubiquitin ligase. Nature 532:127–130
7. Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H (2016) Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov 15:605–619
8. van Montfort RL, Workman P (2009) Structure-based design of molecular cancer therapeutics. Trends Biotechnol 27:315–328
9. Huggins DJ, Sherman W, Tidor B (2012) Rational approaches to improving selectivity in drug design. J Med Chem 55:1424–1444
10. Sanderson K (2013) Irreversible kinase inhibitors gain traction. Nat Rev Drug Discov 12:649–651
11. Shokat K, Velleca M (2002) Novel chemical genetic approaches to the discovery of signal transduction inhibitors. Drug Discov Today 7:872–879
12. Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG et al (2016) Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535:148–152
13. Stoll F, Goller AH, Hillisch A (2011) Utility of protein structures in overcoming ADMET-related issues of drug-like compounds. Drug Discov Today 16:530–538
14. Kurt Yilmaz N, Swanstrom R, Schiffer CA (2016) Improving viral protease inhibitors to counter drug resistance. Trends Microbiol 24:547–557
15. Lahti JL, Tang GW, Capriotti E, Liu T, Altman RB (2012) Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface 9:1409–1437
16. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493–502
17. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880
18. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276–283
19. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196
20. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938–1942
21. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236–4243
22. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW (2004) Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 4:285–299
23. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129–141
24. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O’Brien SG, Litzow M et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540–3546
25. Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW (2007) Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr 63:80–93
26. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S et al (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53:4701–4719
27. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112:859–871
28. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2:95–102
29. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F et al (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463:501–506
30. Jahnke W, Grotzfeld RM, Pelle X, Strauss A, Fendrich G, Cowan-Jacob SW, Cotesta S, Fabbro D, Furet P, Mestan J et al (2010) Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc 132:7043–7048
31. Wylie A, Schoepfer J, Berellini G, Cai H, Caravatti G, Cotesta S, Dodd S, Donovan J, Erb B, Furet P et al (2014) ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with Nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood 124:398
32. Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W et al (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature 543:733–737
33. Hughes TP, Goh Y-T, Ottmann OG, Minami H, Rea D, Lang F, Mauro MJ, DeAngelo DJ, Talpaz M, Hochhaus A et al (2016) Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy. Blood 128:625
34. Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P et al (2015) Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med 21:440–448
35. Chan RJ, Feng GS (2007) PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109:862–867
36. Grossmann KS, Rosario M, Birchmeier C, Birchmeier W (2010) The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 106:53–89
37. Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F et al (2015) PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. Cell Rep 12:1978–1985
38. Scott LM, Chen L, Daniel KG, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J (2011) Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorg Med Chem Lett 21:730–733
39. Grosskopf S, Eckert C, Arkona C, Radetzki S, Bohm K, Heinemann U, Wolber G, von Kries JP, Birchmeier W, Rademann J (2015) Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. ChemMedChem 10:815–826
40. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441–450
41. Sugimoto S, Wandless TJ, Shoelson SE, Neel BG, Walsh CT (1994) Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. J Biol Chem 269:13614–13622
42. Pluskey S, Wandless TJ, Walsh CT, Shoelson SE (1995) Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J Biol Chem 270:2897–2900
43. Garcia Fortanet J, Chen CH, Chen YN, Chen Z, Deng Z, Firestone B, Fekkes P, Fodor M, Fortin PD, Fridrich C et al (2016) Allosteric inhibition of SHP2: Identification of a potent, selective, and orally efficacious phosphatase inhibitor. J Med Chem 59:7773–7782
44. Yu ZH, Xu J, Walls CD, Chen L, Zhang S, Zhang R, Wu L, Wang L, Liu S, Zhang ZY (2013) Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J Biol Chem 288:10472–10482
45. LaRochelle JR, Fodor M, Xu X, Durzynska I, Fan L, Stams T, Chan HM, LaMarche MJ, Chopra R, Wang P et al (2016) Structural and functional consequences of three cancer-associated mutations of the oncogenic phosphatase SHP2. Biochemistry 55:2269–2277
46. Mullard A (2016) 2015 FDA drug approvals. Nat Rev Drug Discov 15:73–76
47. Zhang YJ, Luo L, Desai DD (2016) Overview on biotherapeutic proteins: impact on bioanalysis. Bioanalysis 8:1–9
48. Gilliland GL, Luo J, Vafa O, Almagro JC (2012) Leveraging SBDD in protein therapeutic development: antibody engineering. Methods Mol Biol 841:321–349
49. Robinson LN, Tharakaraman K, Rowley KJ, Costa VV, Chan KR, Wong YH, Ong LC, Tan HC, Koch T, Cain D et al (2015) Structure-guided Design of an Anti-dengue Antibody Directed to a non-immunodominant epitope. Cell 162:493–504
50. Burton DR, Hangartner L (2016) Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol 34:635–659
51. Kwiatkowski W, Gray PC, Choe S (2014) Engineering TGF-beta superfamily ligands for clinical applications. Trends Pharmacol Sci 35:648–657
52. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C et al (2014) Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 32:191–198
53. Wang RE, Wang Y, Zhang Y, Gabrelow C, Zhang Y, Chi V, Fu Q, Luo X, Wang D, Joseph S et al (2016) Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant. Proc Natl Acad Sci U S A 113:11501–11506
54. Lawrence PB, Price JL (2016) How PEGylation influences protein conformational stability. Curr Opin Chem Biol 34:88–94
55. Gilbreth RN, Chacko BM, Grinberg L, Swers JS, Baca M (2014) Stabilization of the third fibronectin type III domain of human tenascin-C through minimal mutation and rational design. Protein Eng Des Sel 27:411–418
56. Apgar JR, Mader M, Agostinelli R, Benard S, Bialek P, Johnson M, Gao Y, Krebs M, Owens J, Parris K et al (2016) Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody. MAbs 8:1302–1318
57. Brader ML, Baker EN, Dunn MF, Laue TM, Carpenter JF (2017) Using X-ray crystallography to simplify and accelerate biologics drug development. J Pharm Sci 106:477–494
58. Weatherill EE, Cain KL, Heywood SP, Compson JE, Heads JT, Adams R, Humphreys DP (2012) Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation. Protein Eng Des Sel 25:321–329
59. Lehmann A, Wixted JH, Shapovalov MV, Roder H, Dunbrack RL Jr, Robinson MK (2015) Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. MAbs 7:1058–1071
60. Gresl T, Storz U, Sandercock C (2016) An update on obtaining and enforcing therapeutic antibody patent claims. Nat Biotechnol 34:1242–1244
61. Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D et al (2013) An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 73:6024–6035
62. Manglik A, Kobilka BK, Steyaert J (2017) Nanobodies to study G protein-coupled receptor structure and function. Annu Rev Pharmacol Toxicol 57:19–37
63. Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth E, Capodieci P, Deplazes-Lauber J, Petropoulos K, Thiel P et al (2016) Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 35:6077–6086
64. Mallon DH, Bradley JA, Taylor CJ, Kosmoliaptsis V (2014) Structural and electrostatic analysis of HLA B-cell epitopes: inference on immunogenicity and prediction of humoral alloresponses. Curr Opin Organ Transplant 19:420–427
65. Pomes A, Chruszcz M, Gustchina A, Minor W, Mueller GA, Pedersen LC, Wlodawer A, Chapman MD (2015) 100 years later: Celebrating the contributions of x-ray crystallography to allergy and clinical immunology. J Allergy Clin Immunol 136(29–37):e10
66. Gala K, Chandarlapaty S (2014) Molecular pathways: HER3 targeted therapy. Clin Cancer Res 20:1410–1416
67. Zhang N, Chang Y, Rios A, An Z (2016) HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin Shanghai 48:39–48
68. Arteaga CL, Engelman JA (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25:282–303
69. Dawson JP, Bu Z, Lemmon MA (2007) Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 15:942–954
70. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541–552
71. Liu P, Cleveland TE, Bouyain S, Byrne PO, Longo PA, Leahy DJ (2012) A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci U S A 109:10861–10866
72. Wang X, Rickert M, Garcia KC (2005) Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310:1159–1163
73. Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G et al (2016) Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med 8:367ra166
74. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A et al (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17:298–310
75. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J (2011) Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20:158–172
76. Mukherjee A, Badal Y, Nguyen XT, Miller J, Chenna A, Tahir H, Newton A, Parry G, Williams S (2011) Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins. PLoS One 6:e16443
77. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301–311
78. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317–328
79. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756–760
80. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116
81. Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12:180–190
82. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P et al (2012) Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 484:529–533
83. Subramaniam S, Earl LA, Falconieri V, Milne JL, Egelman EH (2016) Resolution advances in cryo-EM enable application to drug discovery. Curr Opin Struct Biol 41:194–202
84. Tehan BG, Christopher JA (2016) The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques. Curr Opin Pharmacol 30:8–13
85. Christopher JA, Aves SJ, Bennett KA, Dore AS, Errey JC, Jazayeri A, Marshall FH, Okrasa K, Serrano-Vega MJ, Tehan BG et al (2015) Fragment and structure-based drug discovery for a class C GPCR: Discovery of the mGlu5 negative allosteric modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J Med Chem 58:6653–6664
86. Biankin AV, Piantadosi S, Hollingsworth SJ (2015) Patient-centric trials for therapeutic development in precision oncology. Nature 526:361–370